1 recruiting, 1 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow GDP: new trials by email Literature Review of GDP trials Research Report on GDP
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab - Large Cell Lymphoma, Diffuse, Relapsed Cancer | Phase 2 | Recruiting | Vijendra Singh | 35 | 2023-10-31 | 2026-11-05 |
| Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study GDP, Endostar - Peripheral T-cell Lymphomas | Phase 2 | Unknown | Nanjing NingQi Medicine Science and Technology Co., Ltd. | 60 | 2014-12-01 | 2015-08-11 |
Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasms (1) · Recurrence (1)
Nanjing NingQi Medicine Science and Technology Co., Ltd. (1) · Vijendra Singh (1)
China (1) · United States (1)